Myocardial Ischemic Preconditioning

摘要

Protection of ischemic myocardium through transient antecedent sublethal ischemia (myocardial ischemic preconditioning, IP) is a well established laboratory phenomenon which has caught the attention and imagination of clinicians and researchers throughout the world. The magnitude of protection against ischemic injury conferred by IP is tremendous, far surpassing that offered by past pharmacological therapies. Indirect evidence suggests that IP occurs in human hearts as well. But whether IP is a naturally occurring phenomenon in humans, or is relevant to the practice of clinical medicine, remains unclear.